Dasatinib as first-line treatment for adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemiaRobin Foà, Antonella Vitale, Marco Vignetti et al.|Blood|2011Cited by 460
BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive LeukemiaMatthew S. Zabriskie, Thomas O’Hare, Jeffrey H. Lipton et al.|Cancer Cell|2014Cited by 366
Drug resistance and BCR‐ABL kinase domain mutations in Philadelphia chromosome–positive acute lymphoblastic leukemia from the imatinib to the second‐generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvementSimona Soverini, Giovanni Martinelli, Caterina De Benedittis et al.|Cancer|2013Cited by 143
SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosisGiovanni Martinelli, Simona Soverini|Leukemia|2017Cited by 38
SETD2 non genomic loss of function in advanced systemic mastocytosis is mediated by an Aurora kinase A/MDM2 axis and can be therapeutically targetedManuela Mancini, Simona Soverini|Biomarker Research|2023Cited by 6